Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Determining the effectiveness of increased SMCHD1 expression to suppress DUX4 in FSHD muscle cells and model mice
There are two genetic types of FSHD: FSHD1 and FSHD2. FSHD1 (representing around 95% of FSHD cases) is associated with a loss of repetitive DNA units called D4Z4 on the end of…
Read MoreFSHD myofibers cultured from human xenografts
Much of what we know about DUX4 and its associated toxicity comes from cultured cells from FSHD patients. We basically take cells from a biopsy, grow them on a dish,…
Read MoreInvestigation DUX4 activity during development of hESC-derived skeletal muscle.
In 2011, FSHD Global funded Genea Biocells to isolate the first embryonic stem cells from patients with FSHD. Genea has done an excellent job developing these lines, and sharing them…
Read MoreRNA-mediated Epigenetic Silencing of D4Z4 repeats: Implications for targeted therapy for FSHD
Dr. Jong Won Lim is a Friends of FSH Research Fellow at the Fred Hutchinson Cancer Research Center in Seattle. He is mentored by Dr. Stephen Tapscott and Dr. Galina…
Read MoreValidation of a PPMO morpholino lead compound in an animal model of FSHD
In a very nice review recently published in “Trends in Molecular Medicine”, Lek et al. discussed the over 10 animal models that have been developed for FSHD. That’s quite a…
Read MoreClassification of DUX4 expression in human myofibers derived from xenogeneic muscle cell transplants.
Much of what we know about DUX4 and its associated toxicity comes from cultured cells from FSHD patients. We basically take cells from a biopsy, grow them on a dish,…
Read More